{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
JAN:CARPIPRAMINE MALEATE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Viquidacin (also known as NXL-101), a quinoline antibacterial agent, was studied as a bacterial DNA gyrase and topoisomerase IV inhibitor. Viquidacin showed potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains. The drug participated in phase I clinical trial. Viquidacin achieved homogeneous and potent bactericidal concentrations in human volunteer plasma. However, further, development was discontinued after QT interval prolongation, which was observed in a healthy volunteer.
Status:
Investigational
Source:
NCT01528735: Phase 2 Interventional Completed Hepatitis C, Chronic
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Deleobuvir is a drug for the treatment of Hepatitis C, developed by Boehringer Ingelheim. Deleobuvir is a non-nucleoside HCV NS5B polymerase inhibitor that reversibly and noncovalently binds to the thumb pocket 1. It has shown rapid and strong antiviral activity when administered in combination with peginterferon-a2a and ribavirin. In 2014 Boehringer Ingelheim decided to halt further development of deleobuvir because preliminary analysis of phase 3 clinical trials indicated a low efficacy of the drug.
Status:
Investigational
Source:
NCT02072863: Phase 1/Phase 2 Interventional Completed Multiple Myeloma
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Oprozomib (PR-047) is an orally bioavailable derivative of carfilzomib, with similar biological activity, i.e. inhibition of the chymotrypsin-like activity of the proteasome. It inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Oprozomib (PR-047) is being investigated for the treatment of hematologic malignancies, specifically, multiple myeloma, with Phase I/II trial ongoing.
Status:
Investigational
Source:
NCT03838185: Phase 1 Interventional Completed Alzheimer's Disease
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00565721: Phase 2 Interventional Completed High-grade Glioma
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLUCICLATIDE F-18 is an 18F-radiolabelled synthetic cyclic peptide containing an RGD motif (Arg-Gly-Asp). It may be used as a tracer in positron emission tomography (PET) imaging. The RGD motif of FLUCICLATIDE F-18 selectively binds to the alpha-V/beta-3 integrin, upregulated on tumor cells and endothelial cells of tumor vasculature. Integrins play an important role in tumor angiogenesis and metastasis. Thus, FLUCICLATIDE F-18 is a potential biomarker of therapeutic response to antiangiogenic inhibitors.
Status:
Investigational
Source:
NCT01474941: Phase 1 Interventional Completed Healthy
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
PF-04620110 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that inhibits triacylglycerol synthesis in cells and in rodents. PF-04620110 inhibits DGAT-1 with an IC50 of 19 nM and shows high selectivity versus a broad panel of off-target pharmacologic end points. In vivo DGAT-1 inhibition has been demonstrated through reduction of plasma triglyceride levels in rodents at doses of ≥0.1 mg/kg following a lipid challenge. On the basis of this pharmacologic and pharmacokinetic profile, PF-04620110 has been advanced to human clinical studies. PF-4620110 had been in phase I clinical trials by Pfizer for the treatment of type 2 diabetes. But this research was discontinued in 2011.
Status:
Investigational
Source:
NCT00600743: Phase 2 Interventional Terminated Bulimia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GI-181771X is part of a class of organic compounds known as benzodiazepines. It is a cholecystokinin 1 receptor agonist investigated by GlaxoSmithKline for the treatment of obesity. In one study, GI181771X did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers. This negative result was later assigned to an inadequate trial design rather than compound activity. Gastrointestinal side effects were more common with GI181771X than with placebo treatment. Also, in rodents, morphological changes in the pancreas were observed after administration of GI-181771X, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. In contrast however, pancreatic changes were not observed in monkeys or in human obese patients (in a clinical trial).
Status:
Investigational
Source:
NCT01260480: Phase 2 Interventional Unknown status Carcinoma, Non-Small-Cell Lung
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03191851: Not Applicable Interventional Completed Ascites Hepatic
(2016)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
